Krishna Institute of Medical Sciences Ltd (KIMS) approved a proposal to raise up to ₹1,500 crore through the issuance of equity shares via a qualified institutions placement (QIP) or other permissible routes. According to reports from CNBC TV18 and The Hindu BusinessLine, the hospital chain's board of directors cleared the fundraising plan at a meeting held on Wednesday, March 11, 2026, with the meeting commencing at 12:00 noon and concluding at 1:20 PM. The proposed issue will be subject to shareholder and regulatory approvals as well as the determination of the issue price. As per HomeStocksNews, shareholders will be asked to vote on the proposed fundraise via a postal ballot, with the company also needing to secure clearances from various regulatory bodies. The Finance and Investment Committee of the Board will decide the terms and conditions of the proposed fund raise, as reported by The Hindu BusinessLine.
KIMS reported strong financial results for Q3 FY26 with revenue of ₹600 crore and profit of ₹150 crore for the quarter ended March 31, 2026, as per preliminary reports. This represents a significant improvement from the previous quarter's performance, with the company demonstrating robust operational metrics. The latest financial data shows continued growth momentum for the hospital chain, supporting its expansion plans and justifying the substantial capital raise initiative.
The ₹1,500 crore fundraise will be utilized for capacity expansion, acquiring new facilities, upgrading existing infrastructure, or investing in advanced medical technologies. As reported by HomeStocksNews, this move aims to fuel future growth and signals KIMS Hospitals' intent to pursue ambitious expansion strategies. The company has a history of strategic expansion, including the 2023 acquisition of Sunshine Hospitals which bolstered bed capacity and broadened its operational footprint. Previously, KIMS had tapped capital markets with a Qualified Institutions Placement (QIP) in late 2022 to support earlier growth phases.
Following the announcement, shares of KIMS closed 1.22% lower at ₹680 on the BSE on Wednesday, as reported by The Hindu BusinessLine. According to CNBC TV18, the stock has gained 28.85% over the past year, indicating positive long-term performance despite the recent decline. However, the fundraise is contingent on obtaining necessary member and regulatory approvals, which could face delays or conditions. The final issue price for the QIP or other modes is yet to be determined, introducing price discovery risk. Equity dilution from a large QIP could impact earnings per share (EPS) for existing shareholders if not matched by proportional profit growth.
